Pazopanib Maintenance for SCLC

Phase II Study of Pazopanib Maintenance for SCLC

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01797874

Enrollment

Registered

2013-02-25

Start date

2013-06-30

Completion date

2017-12-31

Last updated

2019-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SCLC

Keywords

pazopanib maintenance, efficacy, SCLC

Brief summary

To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.

Interventions

DRUGPazopanib

Experimental

DRUGPlacebo

placebo arm

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically confirmed SCLC * no disease progression after 4 cycles of etoposide/platinum 1st-line therapy * history of 4 cycles of etoposide/platinum 1st-line therapy * between 21 days and 42 days since C4D1 of etoposide/platinum * no symptomatic brain meta

Exclusion criteria

* poor hepatic, renal function

Design outcomes

Primary

Measure	Time frame
Progression-free survival	12 months

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026